March 20th 2024
Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.
What’s in Your Basket? Tumor Agnostic Trials and the Reshaping of Precision Medicine in Oncology: A Focus on TSC1/2 Mutations
View More
Medical Crossfire®: Why is PSMA so Effective? To Affinity and Beyond
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
No Significant PFS Benefit With Axitinib in First-Line Metastatic RCC
November 19th 2013The second generation VEGFR inhibitor axitinib did not significantly improve progression-free survival in first-line treatment of patients with metastatic renal cell carcinoma compared with patients treated with sorafenib.
PFS May Be Valid Surrogate Endpoint for Overall Survival in Metastatic RCC
October 18th 2013Results of a recent study indicate that patient progression-free survival at 3 months and 6 months was predictive of the overall survival among metastatic RCC patients treated with interferon alpha and bevacizumab.
Tivozanib Fails to Show Overall Survival Difference in Metastatic RCC
September 16th 2013The results of the study comparing Aveo’s tivozanib to sorafenib for the treatment of metastatic renal cell carcinoma showed no improvement in overall survival, the basis for the FDA’s rejection of the company’s new drug application earlier this year.
Pazopanib Noninferior to Sunitinib for Metastatic RCC
September 12th 2013A head-to-head comparison of pazopanib and sunitinib for the treatment of metastatic renal cell carcinoma showed that the two drugs resulted in similar progression-free survival, but also indicated that pazopanib may have a favorable safety profile.
Saving Kidney Tissue May Not Improve Survival in Renal Cancer
August 5th 2013Undergoing nephron-sparing surgery for small renal masses substantially reduced the risk of moderate renal dysfunction compared with radical nephrectomy, but not that of kidney failure among patients enrolled in the EORTC 30904 trial.
Weighing the Evidence for Immune Therapy and Targeted Therapy in Renal Cancer and Melanoma
July 15th 2013Ultimately, as agents in both VEGF-targeted and immunotherapy classes with lower toxicity rates are developed, questions of combination and sequence will inspire clinical investigations of strategies that, it is hoped, will maximize both the quantity and quality of life for patients with RCC. Melanoma therapy drug development continues to lead the way with regard to what is therapeutically possible with immunotherapy-and suggests that HD IL-2 continues to be relevant in today’s treatment landscape.
High-Dose Interleukin-2: Is It Still Indicated for Melanoma and RCC in an Era of Targeted Therapies?
July 15th 2013In this review, we examine the currently approved options available for these disease processes, including the newer agents and selected combinatorial approaches under investigation, and we attempt to identify the role of high-dose IL-2 in the context of current clinical practice.
Bone Metastases Result in Worse Outcomes for RCC Patients
June 28th 2013Bone metastases result in poorer outcomes for those patients with advanced renal cell carcinoma (RCC), who were treated with a molecularly targeted therapy. The results were presented in two separate analyses at the annual ASCO meeting.
RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
June 19th 2013The mTOR inhibitor everolimus failed to prove progression-free survival noninferiority compared with the VEGF-targeting tyrosine kinase inhibitor sunitinib when given as first-line treatment in patients with metastatic renal cell carcinoma.
ASCO: PD-L1 Antibody Elicits Durable Response in RCC
June 19th 2013Researchers observed durable responses in patients with renal cell carcinoma treated with the PD-L1 antibody MPDL3280A. The study, which was presented at the 2013 ASCO Annual Meeting, was one of the few immune therapy trials that allowed patients with non-clear cell histologies and some clinical activity was observed in these patients.
At Increased Cost, Robotic Partial Nephrectomy Improves Kidney Cancer Outcomes
May 8th 2013A study found that robotic partial nephrectomy to remove kidney cancer tumors resulted in better outcomes, but also had significantly higher hospital charges. The data were presented at the annual meeting of the American Urological Association.
Serum Assay Composed of Trio of Biomarkers May Help Detect Kidney Cancers
April 19th 2013A new immunoassay that tests for the presence of nicotinamide N-methyltransferase (NNMT), L-plastin (LCP1), and nonmetastatic cells 1 protein (NM23A) may be an effective method for the early detection of malignant kidney cancer.
Meta-Analysis: Increased Physical Activity Decreases RCC Risk
March 6th 2013High levels of physical activity were linked with a 22% decreased risk for renal cancer, according to a meta-analysis that looked at results from 19 studies that quantified the relationship with physical activity and renal cancer.
A Wife Asks for Futile Therapy for Her Husband, a “Fighter”: How to Respond?
March 2nd 2013One way of framing the ethical question in this case might be: “What are my ethical obligations to provide an anticancer therapy when I think it is unlikely to benefit the patient?” The broader clinical questions involved in this case are fundamentally the same in most patients.